Showing 1,268 results

Filters Content type: News, Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

HIV Dual Therapy Matches Standard Triple Cocktail

Editor's pick
MedPage Today
19 October 2013
New & experimental HIV treatments

CCR5 inhibitor cenicriviroc shows good activity against HIV; new formulation may reduce dropouts

News
18 October 2013
New & experimental HIV treatments

MODERN Study Stopped: An NRTI-Sparing, Two-Drug Initial Regimen Disappoints Again

Editor's pick
NEJM Journal Watch
17 October 2013
The search for a cure

Elusive secret of HIV long-term immunity

Editor's pick
EurekAlert!
17 October 2013
Drug interactions & pharmacokinetics

Merck plans phase III study of once-daily raltegravir (Isentress)

Editor's pick
Merck press release
16 October 2013
New & experimental HIV treatments

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Editor's pick
News Medical Net
15 October 2013
New & experimental HIV treatments

Viriom Reports Clinical Efficacy Data for VM-1500, a New HIV NNRTI

Editor's pick
Marketwired (press release)
8 October 2013
The search for a cure

Gladstone lab uncovers a potential HIV cure — and it's already a drug

Editor's pick
San Francisco Business Times
6 October 2013
PrEP

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?

Editor's pick
The Body Pro
6 October 2013
Injectable & long-acting HIV treatment

Long-acting antiretrovirals may improve survival for people with poor adherence

News
4 October 2013
PrEP science

New integrase inhibitor GSK1265744 safe and well tolerated in eight studies

News
4 October 2013
New & experimental HIV treatments

From sky high to CHAI – what needs to be done about dolutegravir pricing?

Editor's pick
HIV I-Base
2 October 2013
New & experimental HIV treatments

Stribild is effective and well tolerated in older people with HIV

News
2 October 2013
New & experimental HIV treatments

European Commission Approves Gilead Sciences' Tybost(TM), a New Boosting Agent for HIV Therapy

Editor's pick
Gilead press release
26 September 2013
Adherence

Single-tablet regimen improves antiretroviral adherence and reduces hospitalisation

News
26 September 2013
PrEP

PATH Evaluates Janssen’s Rilpivirine as HIV Infection Prophylactic

Editor's pick
Genetic Engineering & Biotechnology News
25 September 2013
New & experimental HIV treatments

CHMP recommends that Vitekta (elvitegravir) should be granted marketing authorisation

Editor's pick
European Medicines Agency
25 September 2013
The search for a cure

Nail Fungus Drug Might Help Against HIV: Study

Editor's pick
WebMD
25 September 2013
Pharmaceutical industry

Seven Ways to Speed up the HIV Treatment Pipeline

Editor's pick
Positive Lite
24 September 2013
Side effects

Switching from Atripla to Eviplera reduces central nervous system side-effects

News
23 September 2013
New & experimental HIV treatments

Good safety profile with long-acting integrase inhibitor, GSK744

Editor's pick
NATAP
19 September 2013
How HIV works

Gene discovery could lead to new types of HIV treatments

Editor's pick
Reuters
19 September 2013
New & experimental HIV treatments

Will Germany Squelch Gilead Hopes For Its Stribild AIDS Drug?

Editor's pick
Pharmalot
19 September 2013
Pregnancy and vertical transmission

Raltegravir appears safe for mothers and babies during pregnancy

News
18 September 2013